Hot Alert: Groupon, Inc. (NASDAQ:GRPN), NVIDIA Corporation (NASDAQ:NVDA), Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD),

Groupon, Inc. (NASDAQ:GRPN) announced that it sold its one billionth Groupon, putting the company in the same group as Apple, McDonalds, Uber, The Beatles, Elvis and other brands and icons that have achieved the billion-sold milestone. The billionth Groupon sold was an $11 for $20 promotion for pizza and Italian food at Pirrone’s Pizzeria in the St. Louis area.

Groupon, Inc. (NASDAQ:GRPN) belongs to Technology sector. Its net profit margin is 0.70% and weekly performance is 10.90%. On last trading day company shares ended up at $4.78. Groupon, Inc. (NASDAQ:GRPN) distance from 50-day simple moving average (SMA50) is -0.36%.

On 27 February, NVIDIA Corporation (NASDAQ:NVDA) is reportedly preparing to debut its next generation Pascal graphics cards at GTC in April with a product launch at Computex in June. Let’s first start with the scheduled debut and demo at this upcoming GTC in April. Whispers have reached us of NVIDIA planning to showcase a Pascal graphics card at the show for the very first time.”

NVIDIA Corporation (NASDAQ:NVDA) shares moved down -1.01% in last trading session and ended the day at $31.36. NVDA Gross Margin is 56.10% and its return on assets is 8.50%. NVIDIA Corporation (NASDAQ:NVDA) quarterly performance is 0.74%.

On 25 February, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it is discontinuing the company’s Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

On 29 February, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares moved down -2.41% and was closed at $0.40.Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) year to date (YTD) performance is -65.80%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its financial results for the fourth quarter and year ended December 31, 2015. ACADIA reported a net loss of $45.8 million, or $0.45 per common share, for the fourth quarter of 2015, compared to a net loss of $28.4 million, or $0.28 per common share, for the fourth quarter of 2014

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ended the last trading day at $17.26. Company weekly volatility is calculated as 8.50% and price to cash ratio as 7.98. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) showed a weekly performance of -14.21%.

Ladenburg Thalmann lowered shares of CTI BioPharma Corp. (NASDAQ:CTIC) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, The Fly reports.

CTI BioPharma Corp. (NASDAQ:CTIC) shares moved down -13.98% in last trading session and ended the day at $0.54. CTIC Gross Margin is 88.20% and its return on assets is -142.60%. CTI BioPharma Corp. (NASDAQ:CTIC) quarterly performance is -56.47%.

Leave a Reply

Your email address will not be published. Required fields are marked *